Zynex, Inc. (ZYXI) announced on Tuesday that it has received FDA clearance for its new prescription-only TensWave device.
This device boasts a portable and user-friendly design, aimed at providing effective pain relief through Transcutaneous Electrical Nerve Stimulation (TENS) therapy. This technology offers patients a safe, effective, and drug-free option for managing pain.
The TensWave enhances Zynex's product lineup, joining the established NexWave device. It offers a premium TENS solution that meets specific insurance reimbursement criteria.
Currently, ZYXI's stock is trading at $7.75, a decline of 1.40%, on the Nasdaq.
